IPSEN S A/S (OTCMKTS:IPSEY) is scheduled to issue its quarterly earnings data before the market opens on Thursday, February 14th.
Shares of IPSEY stock opened at $31.15 on Tuesday. The stock has a market cap of $10.68 billion, a PE ratio of 33.49, a PEG ratio of 0.73 and a beta of 0.64. IPSEN S A/S has a twelve month low of $30.50 and a twelve month high of $44.60.
Separately, Credit Suisse Group cut shares of IPSEN S A/S from a “neutral” rating to an “underperform” rating in a research report on Monday, October 29th.
About IPSEN S A/S
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Featured Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.